FibroGen Stock News

Stocks are at the mercy of many factors, and often, prices are just a poor earnings report or a negative headline away from a significant drop. There are times when nobody has any way of preparing.

FibroGen Inc said on Monday it is regaining rights to the anemia drug, roxadustat, from AstraZeneca after the companies mutually agreed to terminate their collaboration agreement.

SAN FRANCISCO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce fourth quarter and full year 2023 financial results on Monday, February 26 after the market close. FibroGen

FibroGen, Inc. (FGEN) Q3 2023 Earnings Call Transcript

The headline numbers for FibroGen (FGEN) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street est

SAN FRANCISCO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2023 financial results on Monday, November 6 after the market close. FibroGen will also c

While a contentious topic, investors seeking long-term success must frequently consider stocks to sell. Similar to changing the oil in a combustion-powered car, you've got to keep the overall machiner

FibroGen (FGEN) falls 22.7% as its late-stage study of pamrevlumab for the treatment of ambulatory patients with Duchenne muscular dystrophy fails to meet the primary endpoint.

FibroGen Inc (NASDAQ:FGEN) plummeted some 27% lower in Wednesday's early deals after revealing that its intended treatment for Duchenne muscular dystrophy failed to achieve primary and secondary endpo

Shares of FibroGen Inc. FGEN, +3.23% fell 23% premarket on Wednesday after the company said its investigational treatment for Duchenne muscular dystrophy failed to meet its primary and secondary endpo

The heavy selling pressure might have exhausted for FibroGen (FGEN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts i

FibroGen, Inc. (NASDAQ:FGEN ) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Company Participants David DeLucia - Head of Corporate FP&A / Investor Relations Enrique Conterno - Chief Execu

The headline numbers for FibroGen (FGEN) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimate

FibroGen (FGEN) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $0.78 per share a year ago.

SAN FRANCISCO, July 24, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2023 financial results on Monday, August 7 after the market close. FibroGen will also co